Arja Ter Elst

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Evaluation of homologous recombination testing in ovarian carcinoma.

Evaluation of homologous recombination testing in ovarian carcinoma.

Journal: Virchows Archiv : an international journal of pathology

Published: November 27, 2025

Influence of pre-analytical factors on the success rates of smMIP and MLPA analyses in epithelial ovarian cancer.

Influence of pre-analytical factors on the success rates of smMIP and MLPA analyses in epithelial ovarian cancer.

Journal: Virchows Archiv : an international journal of pathology

Published: July 03, 2025

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 24, 2025

Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing.

Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing.

Journal: The journal of pathology. Clinical research

Published: August 07, 2024

BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study.

BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study.

Journal: Cancers

Published: March 29, 2024

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.

Journal: Nature communications

Published: February 23, 2024

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.

Journal: NPJ precision oncology

Published: January 08, 2024

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.

Next generation sequencing of high-grade adult-type diffuse glioma in the Netherlands: interlaboratory variation in the primary diagnostic and recurrent setting.

Journal: Journal of neuro-oncology

Published: December 15, 2023

Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.

Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.

Journal: Molecular oncology

Published: October 10, 2023

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.

Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.

Journal: The Journal of pathology

Published: May 26, 2023

BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients.

BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 03, 2023

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 21, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026